klini^ko ispituvawe na terapiskata efikasnost, podnoslivost i

Clinical trial on terapeutic efficacy, tolerability and safety of peroral solutions Varumin 1 and 2 (Interevrogeneks)
in a combined treatment with polyvitamin – antioxidative therapy in patients with biologicaly
(PCR) detected HPV infection of high-risk type, with or without biopticaly verified CIN I
Analysis with Wilcoxon Matched Pairs Test presented statistical significant differences between
HPV PCR typization on the first and the second check-up among patients treated with the
investigated agent. (T = 14,00 Z = 4,204 p = 0,000026)
Analysis with Wilcoxon Matched Pairs Test presented statistical significant differences between
HPV PCR typization on the first and the third check-up among patients treated with the
investigated agent. The difference is more significant on the third check-up compared to the first.
(T = 17,50 Z = 4,787 p = 0,000002)
Analysis with Wilcoxon Matched Pairs Test did not present statistical significant differences
between HPV PCR typization on the second and the third check-up among patients treated
with the investigated agent. (T = 4,50 Z = 1,890 p = 0,0587)
Table 5. Distributions of patients treated with the investigated agent according to HPV PCR
typization on first, second and third check up
HPV PCR typization of the group treated with
the investigated agent
I II III
n % n % n %
Negative findings ( 0 ) 0 0 29 70.73 33 89.2
Persisistence of the same HPV type ( 1 ) 46 100 11 26.83 3 8.1
Occurrence of a new high-risk HPV type ( 2 ) 0 0 1 2.44 1 2.7
total 46 100 41 100 37 100
Chart 5. Distributions of patients treated with the investigated agent according to HPV PCR
typization on first, second and third check up
50
45
40
35
30
25
20
15
10
5
0
0
46
0
29
11
University Gynecology and Obstetrics Clinic, Vodnjanska bb, University St. Cyrillus and Methodius, Skopje,
Macedonia
1
33
I II III
3
1
0
1
2
28